Stocktoria
Opus Genetics, Inc. IRD
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2004-11-30
Opus Genetics, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -271.9% | -564.7% | -55.5% | 45.7% | -3854.8% |
| Net margin | -349.3% | -523.4% | -52.4% | 44.9% | -9625.3% |
| Return on assets | -98.7% | -156.1% | -18.5% | 36.5% | -217.4% |
| Return on equity | -323.1% | -855.6% | -20.0% | 38.7% | -255.1% |
| Debt / equity | 0.07× | 0.00× | — | — | — |
| Current ratio | 6.43 | 3.24 | 13.35 | 17.79 | 6.76 |
| Revenue growth | 29.1% | -42.3% | -52.2% | 6665.7% | — |
Source: SEC EDGAR filings · CIK 0001228627 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.